ADC Therapeutics SA (ADCT)

USD 1.21

(-0.82%)

Operating Income Summary of ADC Therapeutics SA

ADC Therapeutics SA's latest annual operating income in 2023 was -165.98 Million USD , down -34.26% from previous year.
ADC Therapeutics SA's latest quarterly operating income in 2024 Q2 was -29.04 Million USD , up 13.6% from previous quarter.
ADC Therapeutics SA reported an annual operating income of -123.62 Million USD in 2022, up 52.76% from previous year.
ADC Therapeutics SA reported an annual operating income of -261.72 Million USD in 2021, down -19.36% from previous year.
ADC Therapeutics SA reported a quarterly operating income of -29.04 Million USD for 2024 Q2, up 13.6% from previous quarter.
ADC Therapeutics SA reported a quarterly operating income of -39.78 Million USD for 2023 Q2, up 22.85% from previous quarter.

Annual Operating Income Chart of ADC Therapeutics SA (2023 - 2017)

Historical Annual Operating Income of ADC Therapeutics SA (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	-165.98 Million USD	-34.26%
2022	-123.62 Million USD	52.76%
2021	-261.72 Million USD	-19.36%
2020	-219.26 Million USD	-83.64%
2019	-119.39 Million USD	5.19%
2018	-125.94 Million USD	-37.39%
2017	-91.67 Million USD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-33.61 Million USD	15.92%
2024 Q2	-29.04 Million USD	13.6%
2023 Q2	-39.78 Million USD	22.85%
2023 Q3	-37.4 Million USD	5.99%
2023 Q1	-51.57 Million USD	-380.28%
2023 FY	-165.98 Million USD	-34.26%
2023 Q4	-39.97 Million USD	-6.88%
2022 Q4	-10.73 Million USD	-256.37%
2022 Q3	6.86 Million USD	109.89%
2022 Q2	-69.41 Million USD	-71.96%
2022 FY	-123.62 Million USD	52.76%
2022 Q1	-40.36 Million USD	35.71%
2021 FY	-261.72 Million USD	-19.36%
2021 Q3	-57.79 Million USD	18.0%
2021 Q1	-70.66 Million USD	9.41%
2021 Q4	-62.78 Million USD	-8.63%
2021 Q2	-70.48 Million USD	0.26%
2020 Q1	-43.88 Million USD	-22.82%
2020 FY	-219.26 Million USD	-83.64%
2020 Q2	-44.94 Million USD	-2.42%
2020 Q3	-52.42 Million USD	-16.64%
2020 Q4	-78 Million USD	-48.78%
2019 Q4	-35.73 Million USD	-8.8%
2019 Q3	-32.84 Million USD	-37.49%
2019 Q2	-23.88 Million USD	6.0%
2019 Q1	-25.41 Million USD	18.63%
2019 FY	-119.39 Million USD	5.19%
2018 Q3	-31.23 Million USD	1.24%
2018 Q2	-31.62 Million USD	0.0%
2018 FY	-125.94 Million USD	-37.39%
2018 Q1	-31.62 Million USD	0.0%
2018 Q4	-31.23 Million USD	0.0%
2017 FY	-91.67 Million USD	0.0%

Peer Operating Income Comparison of ADC Therapeutics SA

Name	Operating Income	Operating Income Difference
Alto Neuroscience, Inc.	-37.8 Million USD	-339.012%
Annovis Bio, Inc.	-45.03 Million USD	-268.571%
Biohaven Pharmaceutical Holding Company Ltd.	-436.05 Million USD	61.934%
Ginkgo Bioworks Holdings, Inc.	-864.4 Million USD	80.798%
Nuvation Bio Inc.	-99.82 Million USD	-66.282%
Nuvation Bio Inc.	-99.82 Million USD	-66.282%
Arcus Biosciences, Inc.	-340 Million USD	51.181%
Zymeworks Inc.	-138.05 Million USD	-20.234%